QIP-MS: A specific, sensitive, accurate, and quantitative alternative to electrophoresis that can identify endogenous m-proteins and distinguish them from therapeutic monoclonal antibodies in patients being treated for multiple myeloma

North, Susan M; Barnidge, David R.; Brusseau, S.; Patel, R. C.; Haselton, Michelle; Chateau, B. Du; Wallis, Gregg; Harding, SJ; Sakrikar, Dhananjay; Ashby, J. P.

doi:10.1016/j.cca.2019.03.920

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An alternative method, Quantitative Immunoprecipitation MS (QIP-MS), uses polyclonal antibody-based technology to detect and quantify intact Ig in serum based on their molecular mass. Each M-protein is specific to each PC clone and differentiated from mAbs drugs applied in the clinical setting, allowing their tracing over time [105]. This method is currently being evaluated for MRD assessment in the context of clinical trials and has shown good concordance with BM NGF MRD results [106,107].…”

Section: Future Of Mrd Testing: Beyond Bm Assessmentmentioning

confidence: 99%

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?

Caetano

Barahona

Lúcio

et al. 2022

Hemato

View full text Add to dashboard Cite

The introduction of new and more effective therapeutic options for Multiple Myeloma (MM) has significantly deepened and prolonged patients’ remission. As currently used treatment protocols induce high rates of complete responses, Measurable Residual Disease (MRD) assessment has become essential to enhance the evaluation of treatment efficacy. Detection of MRD has improved with the development of highly sensitive and standardized techniques such as Next Generation Flow or Next Generation Sequencing, complemented by functional imaging techniques. These advances offer a valuable opportunity to further optimize criteria of response to treatment. Currently, extensive data demonstrate that MRD status is a valuable prognostic factor of survival. Since MRD represents a real measurement of disease burden, its incorporation in clinical trials to guide treatment decisions will certainly translate into clinical benefits. Sustained MRD negativity can be used to consider optimal candidates for treatment discontinuation, whereas MRD positive high-risk patients may have access to novel immunotherapeutic strategies such as bispecific drugs or CAR T cell therapy. In this review, we describe the available techniques to detect MRD, address the current data regarding MRD as a surrogate endpoint within clinical trials, examine how MRD can be introduced into the clinical management of MM patients, and discuss the future of MRD monitoring.

show abstract

Section: Future Of Mrd Testing: Beyond Bm Assessmentmentioning

confidence: 99%

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?

Caetano

Barahona

Lúcio

et al. 2022

Hemato

View full text Add to dashboard Cite

show abstract

“…Each M-protein is characterized by a specific sequence of amino acids determined during somatic recombination and unique to each plasma cell clone, allowing single-clone tracking over time with high analytical sensitivity. QIP-MS provides a reproducible and sensitive alternative to conventional electrophoresis of serum samples from MM patients [18].…”

Section: Pet-ctmentioning

confidence: 99%

The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study

Rasmussen

Askeland

Schjesvold

2020

Hemato

View full text Add to dashboard Cite

The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment.

show abstract